<DOC>
	<DOCNO>NCT00398905</DOCNO>
	<brief_summary>Patients undergo surgery , especially hip knee surgery , high risk VTE . The administration drug thromboprophylaxis , heparin , significantly lower risk , heparin apply injection skin . The purpose study compare safety efficacy BAY 59-7939 safety efficacy license drug enoxaparin find optimal dose BAY 59-7939 anticipate phase III trial . Enoxaparin , so-called low molecular weight heparin , approve widely use area thromboprophylaxis give daily subcutaneously . In study 5 different dos investigational drug BAY 59-7939 test comparison Enoxaparin . The following dos BAY 59-7939 test : 2.5 mg twice daily ( 5 mg total daily dose ) ; 5 mg twice daily ( 10 mg total daily dose ) , 10 mg twice daily ( 20 mg total daily dose ) , 20 mg twice daily ( 40 mg total daily dose ) 30 mg twice daily ( 60 mg total daily dose ) . This study run approximately 7 month number country . In total , 726 patient enrol study .</brief_summary>
	<brief_title>Dose-Ranging Study BAY 59-7939 Prevention VTE Patients Undergoing Elective Total Hip Replacement</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Male patient age 18 year postmenopausal female patient Patients schedule elective primary total hip replacement ( cement noncemented prosthesis Patients write informed consent participation receive detailed write oral previous information study specific procedures Any VTE prior randomization Myocardial infarction ( MI ) TIA ischaemic stroke within last 6 month prior randomisation History heparininduced thrombocytopenia , allergy heparin Intracerebral intraocular bleeding within last 6 month prior randomisation History gastrointestinal disease gastrointestinal bleeding within last 6 month prior study History presence gastrointestinal disease could result impaired absorption study drug ( e.g . severe active inflammatory bowel disease , short gut syndrome ) Amputation one leg Heart insufficiency NYHA IIIIV Congenital acquire haemorrhagic diathesis ( PT INR/aPTT within normal limit ) include patient acquire congenital thrombopathy Thrombocytopenia ( platelet &lt; 100.000/Âµl ) Macroscopic haematuria . Allergy contrast medium . Severe hypertension ( SBP &gt; 200mmHg , DBP &gt; 100 mmHg ) Impaired liver function ( transaminases &gt; 2 x ULN ) Impaired renal function ( serum creatinine &gt; 1.5 x ULN creatinine clearance &lt; 30 ml/min ) Active malignant disease Presence active peptic ulcer gastrointestinal disease increase risk gastrointestinal bleeding Body weight &lt; 45 kg Drug alcohol abuse Patients stop therapy ( opinion investigator/ physician ) anticoagulant ( e.g . phenprocoumon , warfarinsodium , heparins factor Xa inhibitor study medication ) fibrinolytic therapy exclude study Therapy acetylic salicylic acid thrombocyte aggregation inhibitor ( e.g . clopidogrel , dipyridamole ticlopidine ) stop one week enrolment . Patients able stop ASA therapy exclude All drug influence coagulation , ( exception : NSAIDs half life &lt; 17 hr allow ) Systemic topical treatment azole compound ( e.g . ketoconazole , fluconazole , itraconazole ) strong CYP3A4 inhibitor e.g . HIVprotease inhibitor . Azole compound strong CYP3A4 inhibitor Therapy another investigational product within 30 day prior start study Planned intermittent pneumatic compression active treatment period Planned epidural anaesthesia indwell epidural catheter ( spinal epidural anaesthesia without indwell catheter allow ) Concomitant participation another trial study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Prevention venous thromboembolism</keyword>
</DOC>